newsfilter
← Latest News
GlobeNewswire·

IMMX ALERT: Immix Biopharma Investigated for Securities Fraud Violations by Block & Leviton; Investors Should Contact the Firm

  • Block & Leviton is investigating Immix Biopharma (NASDAQ: IMMX) for potential securities law violations.
  • An executive known as "Richard Graydon" was allegedly a fugitive named Ronald Fischer operating under a false identity.
  • Immix Biopharma terminated the individual on July 17, 2026, claiming his short tenure had no material effect on the business.
  • Immix shares fell approximately 10.83% on the day the report circulated.
  • Investors who purchased Immix common stock & saw their shares decline may be eligible to recover losses.
  • Block & Leviton may file an action to recover losses on behalf of defrauded investors.
  • Eligible investors can contact the firm via email at shareholders@blockleviton.com or by phone at (888) 256-2510.
  • Whistleblowers providing original non-public information to the SEC may receive rewards of up to 30% of any successful recovery.